Cargando…

Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway

BACKGROUND: A major therapeutic challenge for breast cancer is the ability of cancer cells to evade killing of conventional chemotherapeutic agents. We have recently reported the actin-bundling protein (fascin) as a major regulator of breast cancer metastasis and survival. METHODS: Survival of breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghebeh, H, Al-Khaldi, S, Olabi, S, Al-Dhfyan, A, Al-Mohanna, F, Barnawi, R, Tulbah, A, Al-Tweigeri, T, Ajarim, D, Al-Alwan, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200093/ https://www.ncbi.nlm.nih.gov/pubmed/25117814 http://dx.doi.org/10.1038/bjc.2014.453

Ejemplares similares

Fascin Is a Key Regulator of Breast Cancer Invasion That Acts via the Modification of Metastasis-Associated Molecules
por: Al-Alwan, Monther, et al.
Publicado: (2011)

β1 Integrin is essential for fascin‐mediated breast cancer stem cell function and disease progression
por: Barnawi, Rayanah, et al.
Publicado: (2019)

Fascin Activates β-Catenin Signaling and Promotes Breast Cancer Stem Cell Function Mainly Through Focal Adhesion Kinase (FAK): Relation With Disease Progression
por: Barnawi, Rayanah, et al.
Publicado: (2020)

Comprehensive Transcriptome and Pathway Analyses Revealed Central Role for Fascin in Promoting Triple-Negative Breast Cancer Progression
por: Barnawi, Rayanah, et al.
Publicado: (2021)

Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer
por: Ghebeh, Hazem, et al.
Publicado: (2021)

PD‐L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
por: Almozyan, Sheema, et al.
Publicado: (2017)

Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells
por: Alsuliman, Abdullah, et al.
Publicado: (2015)

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway
por: Presneau, N, et al.
Publicado: (2009)

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate
por: Falasca, M, et al.
Publicado: (2010)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death
por: Hotfilder, M, et al.
Publicado: (2005)

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation
por: Seront, E, et al.
Publicado: (2013)

Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination
por: Al Sayed, Adher D., et al.
Publicado: (2019)

Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues
por: Ghebeh, Hazem, et al.
Publicado: (2021)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs
por: Mellor, H R, et al.
Publicado: (2005)

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
por: Chatelut, E, et al.
Publicado: (2012)

FOXP3(+ )T(regs )and B7-H1(+)/PD-1(+ )T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
por: Ghebeh, Hazem, et al.
Publicado: (2008)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
por: Yoon, C, et al.
Publicado: (2015)

Profiling of normal and malignant breast tissue show CD44(high)/CD24(low) phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers
por: Ghebeh, Hazem, et al.
Publicado: (2013)

Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
por: Shannon, A M, et al.
Publicado: (2005)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis
por: Mansour, Fatmah A., et al.
Publicado: (2020)

Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule
por: Ghebeh, Hazem, et al.
Publicado: (2010)

Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer
por: Beale, Gary, et al.
Publicado: (2016)

Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma
por: Erlich, R B, et al.
Publicado: (2012)

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
por: García-Martínez, J M, et al.
Publicado: (2011)

Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy
por: Shehata, M, et al.
Publicado: (2009)

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
por: D'Amato, V, et al.
Publicado: (2014)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy
por: Fareed, K R, et al.
Publicado: (2010)

Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience
por: Elkum, Naser, et al.
Publicado: (2007)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
por: Yang, X, et al.
Publicado: (2008)

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
por: Atmaca, A, et al.
Publicado: (2007)

Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer
por: Lin, H-J, et al.
Publicado: (2005)

Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers
por: Al-Attar, A, et al.
Publicado: (2010)

Aurora B expression modulates paclitaxel response in non-small cell lung cancer
por: Al-Khafaji, Ahmed SK, et al.
Publicado: (2017)

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer
por: Diaz, R, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_1occc66hin7cfp653027t5dhuj